CD38 and acute myeloid leukemia: Regarding other AML antigens, preclinical studies have demonstrated anti-leukemic activity for CAR-T cells against ADGRE2 [82], CD7 [36], FLT3 [83, 84], Lewis Y [44], CD38 [58, 85], and NKG2DL [86] (Table 2).